X Fragile Syndrome Clinical Trial
— SXF2-8Official title:
Clinical Trials Phase III, Double Blind, Crossover to Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome
NCT number | NCT02942498 |
Other study ID # | SXF2-8 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | October 31, 2018 |
The purpose of this study is to determine vitamin C and vitamin E in combination are effective in the treatment of cognitive and behavior disorder in children with fragile X syndrome.
Status | Completed |
Enrollment | 34 |
Est. completion date | October 31, 2018 |
Est. primary completion date | September 25, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 8 Years |
Eligibility | Inclusion Criteria: 1. Diagnosis of Fragile X syndrome by genetic testing of molecular biology, full mutation result methylation. 2. Having an older age of 1 year and less than 9 years 3. Having signed the informed consent document before starting their participation in the trial. Exclusion Criteria: 1. Any advanced, severe or unstable disease. 2. Individuals with other psychiatric diagnosis as the first diagnosis. 3. It have been suffered serious medical problems in the last 12 months. 4. Be taking more than 100 mg of vitamin E or C a day in the last month. 5. Having physical, mental or sensory impairments that prevent the assessment of effectiveness. 6. Hypersensitivity to any component of the preparation. 7. Liver failure or severe renal or previous history of kidney stones. 8. Any treatment regimen, including treatment with psychotropic drugs and / or anticonvulsant therapy that has not been stable for a period = 4 weeks before randomization. 9. Current treatment with more than two psychoactive medications, excluding medication used specifically for the control of seizures. 10. Hypoprothrombinemia secondary to vitamin K deficiency 11. Sensitivity to any of the compounds of formula treatment. 12. Patients diagnosed with congenital or idiopathic methemoglobinemia for diagnosis of glucose-6-phosphate dehydrogenase deficiency. 13. Use of oral anticoagulants, iron or vitamin A. 14. Forecast initiate or change pharmacological or no pharmacological interventions during the course of the study. 15. Patients weighing less than 4.2 kg |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Regional de Málaga | Malaga | Málaga |
Lead Sponsor | Collaborator |
---|---|
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Delos Clinical |
Spain,
Barger SW, Goodwin ME, Porter MM, Beggs ML. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem. 2007 Jun;101(5):1205-13. Epub 2007 Mar 30. — View Citation
Castilla P, Dávalos A, Teruel JL, Cerrato F, Fernández-Lucas M, Merino JL, Sánchez-Martín CC, Ortuño J, Lasunción MA. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr. 2008 Apr;87(4):1053-61. — View Citation
Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004 Jan;61(1):82-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Autism Treatment Evaluation Checklist (ATEC). | 32 weeks | ||
Primary | Global Clinical Impression (GCI) | 32 weeks | ||
Primary | Peabody Picture Vocabulary Test (PiVT) | 32 weeks | ||
Primary | Battelle developmental inventory screening | 32 weeks | ||
Primary | Vineland Adaptive Behavior Scales | 32 weeks | ||
Primary | Adverse event reported | 32 weeks | ||
Primary | Quantitative Checklist for Autism in Toddlers (Q-Chat) test | 32 weeks | ||
Secondary | Golberg scale GHQ-28 | 32 weeks | ||
Secondary | Quality life SF36 test | 32 weeks | ||
Secondary | Psychological General Well-Being Index | 32 weeks | ||
Secondary | Sleep Disturbance Scale for Children | 32 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04768803 -
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
|